AI Article Synopsis
- - This study analyzed the safety of adalimumab, a medication used for various conditions, by reviewing randomized controlled trials to assess its infection risk.
- - A total of 21 high-quality trials were examined, revealing a slight increase in the risk of infection in patients taking adalimumab, particularly at normal dosages and in those with psoriasis or rheumatoid arthritis.
- - The researchers concluded that more studies with longer treatment durations and higher doses are necessary to determine if the infection risk is significantly elevated among adalimumab users.
Article Abstract
Background: This study assessed the safety of adalimumab in different dosages and durations of treatment.
Methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to explore the infection risk in people who received adalimumab. We searched the Cochrane Library, PubMed, and EMBASE from inception to December 8, 2020. Summary estimates were obtained using meta-analysis with a random-effects model.
Results: Twenty-one RCTs, considered to be of high quality, were analyzed. We found that there was a risk of infection (RR: 1.10, 95% CI: 1.02-1.18). In the stratified analysis, we found an increase in infection among those that received normal dosage (RR: 1.13, 95% CI: 1.04-1.23), and in patients with psoriasis (RR: 1.13, 95% CI: 1.00-1.35) and rheumatoid arthritis (RR: 1.23, 95% CI: 1.06-1.41), but not in those that received high doses and other criteria. In the meta-regressions, intervention duration was not related to changes in incidence risk.
Conclusions: Trials that have a longer treatment duration and higher doses are needed to clarify whether patients that received adalimumab had an elevated risk of general infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14787210.2021.1902804 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!